Immunome Inc. (IMNM) stock prices were up by 5.96% shortly after market trading commenced on September 7th 2021. This brought the price per share up to USD$16.00 early on in the trading day.
IMM-BCP-01 Effective against Covid-19 Strains
The biopharmaceutical company announced on September 7th 2021 that its three-antibody cocktail (IMM-BCP-01) exhibited potent neutralizing activity against the Lambda and Delta variants of Covid-19. The results came from pre-clinical testing conducted by the company on lentiviral-based pseudovirus. The treatment consists of three antibodies that bind to non-overlapping regions of the spike protein and exhibit synergistic activity against various strains of the global coronavirus.
Scope of IMNM Stock’s Treatment
IMM-BCP-01 is continuing to demonstrate its potential for the broad neutralization of various emerging Covid-19 variants in preclinical testing, the most recent of which were the highly concerning Lambda and Delta plus variants. The United States has been seeing an increasing number of cases of the Delta variant, making it the dominant straint, while the Lambda variant is proliferating South America as a variant of interest, as designated by the World Health Organization (WHO).
Continued Trajectory of Success
The treatment was designed to be resistant to variants of the coronavirus and preclinical data thus far has been highly encouraging. The results instill further confidence that the treatment could be essential in curbing and dealing with the persistent coronavirus pandemic. The treatment has already demonstrated an ability to neutralize all other current Centers for Disease Control (CDC) variants of concern during the pre-clinical testing phase. The project was funded by the United States Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical, in conjunction with the Defense Health Agency.
About IMNM Stock
The biopharmaceutical company leverages its human memory B cell platform to facilitate the discovery and development of first-in-class antibody therapeutics. Aiming to change the way diseases are treated, IMNM stock’s initial focus is on developing treatments to address oncology and infectious diseases, including Covid-19.
Future Outlook for IMNM Stock
The company reported a promising quarter, consolidated by the success of its flagship treatment in neutralizing emerging Covid-19 variants. IMNM stock is poised to capitalize on the opportunities afforded to it as the global pandemic continues to persist. Investors are hopeful that the company will be able to continue their trajectory of success over the long term.
